Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis

NCT02895100 is registered in ClinicalTrials.gov with Protagonist Therapeutics, Inc. as lead sponsor.

NCT NCT02895100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02895100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis
Lead sponsor
Protagonist Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2016
Completion date
March 26, 2018
Enrollment
98 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis